Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?


Cite item

Full Text

Abstract

In the review article are provided the approaches to the therapy for improvement of prognosis in patients with peripheral and multifocal atherosclerosis which are available now; some limitations and a real situation are designated for the antithrombotic therapy in this category of patients. According to the clinical trial COMPASS the prospects of wide use of a combination of acetylsalicylic acid and a rivaroxsaban of 2.5 mg 2 times a day in the patients with chronic coronary heart disease and/or symptom peripheral atherosclerosis are designated.

About the authors

O L Barbarash

Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University

Kemerovo, Russia

V V Kashtalap

Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University

Kemerovo, Russia

References

  1. Барбараш О.Л., Кашталап В.В. Выявление латентного некоронарного атеросклероза у пациентов с острым коронарным синдромом. Есть ли смысл? Комплексные проблемы сердечно - сосудистых заболеваний. 2012;(1):12-6.
  2. Eagle K.A, Rihal C.S, Foster E.D, Mickel M.C, Gersh B.J. Long - term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol. 1994;23:1091-5. doi: 10.1016/0735-1097(94)90596-7
  3. Smolderen K.G, Bell A, Lei Y, Cohen E.A, Steg P.G, Bhatt D.L, Mahoney E.M, on behalf of the REACH registry investigators. One - year costs associated with cardiovascular disease in Canada: Insights from the RE-duction of Atherothrombosis for Continued Health (REACH) registry. Can J Cardiol. 2010 Oct;26(8):e297-e305. doi: 10.1016/s0828-282x(10)70437-2
  4. Ohman E.M, Bhatt D.L, Steg P.G, Goto S, Hirsch A.T, Liau C.S, et al; REACH Registry Investigators. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events - study design. Am Heart J. 2006 Apr;151(4):786.e1-10. doi: 10.1016/j.ahj.2005.11.004
  5. Manfrini O, Amaduzzi P.L, Cenko E, Bugiardini R. Prognostic implications of peripheral artery disease in coronary artery disease. Curr Opin Pharmacol. 2018;39:121-8. doi: 10.1016/j.coph.2018.04.005
  6. Барбараш О.Л., Кашталап В.В. Пациент с ишемической болезнью сердца и мультифокальным атеросклерозом. Как оптимизировать прогноз? Медицинский совет. 2018;16:32-8. doi: 10.21518/2079-701X-2018-16-32-38
  7. Abtan J, Bhatt D.L, Elbez Y, Sorbets E, Eagle K, Reid C.M, et al; REACH Registry Investigators. Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: insights from the REACH Registry. Clin Cardiol. 2017;40:710-8. doi: 10.1002/clc.22721
  8. Безденежных А.В., Сумин А.Н., Иванов С.В., Барбараш О.Л. Предикторы госпитальных осложнений коронарного шунтирования: роль мультифокального атеросклероза. Сибирский медицинский журнал. 2016;31(1):35-41.
  9. Гайфулин Р.А., Сумин А.Н., Иванов С.В., Барбараш Л.С. Выживаемость после хирургического лечения больных с мультифокальным атеросклерозом в различных возрастных группах. Комплексные проблемы сердечно - сосудистых заболеваний. 2017;6(2):6-18.
  10. Барбараш О.Л., Кашталап В.В. Атеросклероз периферических артерий и артериальная гипертония. Особенности антигипертензивной терапии. Медицинский алфавит. 2019;1(3):12-6. doi: 10.33667/2078-5631-2019-1-3(378)-12-16
  11. Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763-821. doi: 10.1093/eur-heartj/ehx095
  12. Welten G.M, Chonchol M, Schouten O, Hoeks S, Bax J.J, van Domburg R.T, et al. Statin use is associated with early recovery of kidney injury after vascular surgery and improved long - term outcome. Nephrol Dial Transplant. 2008 Dec;23(12):3867-73. doi: 10.1093/ndt/gfn381
  13. Kumbhani D.J, Steg P.G, Cannon C.P, et al. REACH Registry Investigators. Statin therapy and long - term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35(41):2864-72. doi: 10.1093/eurheartj/ehu080
  14. Сумин А.Н., Косова М.А., Медведева Ю.Д., Щеглова А.В., Макаров С.А., Артамонова Г.В., Барбараш Л.С. Амбулаторное наблюдение больных атеросклерозом нижних конечностей с позиций кардиолога. Российский кардиологический журнал. 2016;21(12):58-63. doi: 10.15829/1560-4071-2016-12-58-63
  15. Gerhard-Herman M.D, Gornik H.L, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69:1465-508. doi: 10.1016/j.jacc.2016.11.007
  16. Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte M.S, Pomposelli F.B, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61:2S-41S. doi: 10.1016/j.jvs.2014.12.006
  17. Brass E.P, Hiatt W.R. Aspirin monotherapy should not be recommended for cardioprotection in patients with symptomatic peripheral artery disease. Circulation. 2018 Mar 20;137(12):1304. doi: 10.1161/CIRCULA-TIONAHA.117.032707
  18. Fox K.A, Carruthers K.F, Dunbar D.R, Graham C, Manning J.R, De Raedt H, et al. Underestimated and underrecognized: the late consequences of acute coronary syndrome (GRACE UKBelgian Study). Eur Heart J. 2010;31:2755-64. doi: 10.1093/eurheartj/ehq326
  19. Bhatt D.L, Eagle K.A, Ohman E.M, Hirsch A.T, Goto S, Mahoney E.M, et al. REACH Registry Investigators Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350-7. doi: 10.1001/jama.2010.1322
  20. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post - myocardial infarction patients: nationwide real world data demonstrate the importance of a long - term perspective. Eur Heart J. 2015;36:1163-70. doi: 10.1093/eurheartj/ehu505
  21. Rapsomaniki E, Thuresson M, Yang E, Blin P, Hunt P, Chung S-C, et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin Outcomes. 2016;2:172-83. doi: 10.1093/ehjqcco/qcw004
  22. Барбараш О.Л., Кашталап В.В. Клопидогрел в составе двойной дезагрегантной терапии при ОКС: обоснованный выбор в сложных клинических ситуациях. Медицинский совет. 2019;(5):20-9. doi: 10.21518/2079-701X-2019-5-20-29/
  23. Gurbel P.A, Fox K.A.A, Tantry U.S, Ten Cate H, Weitz J.I. Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. Circulation. 2019 Apr 30;139(18):2170-85. doi: 10.1161/CIRCULATIONAHA.118.033580
  24. Wallentin L, Becker R.C, Budaj A, Cannon C.P, Emanuelsson H, Held C, et al; for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-57. doi: 10.1056/NEJMoa0904327
  25. Bonaca M.P, Bhatt D.L, Cohen M, Steg P.G, Storey R.F, Jensen E.C, et al; for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long - term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800. doi: 10.1056/NEJMoa1500857
  26. Hiatt W.R, Fowkes F.G.R, Heizer G, Berger J.S, Baumgartner I, Held P, et al; for the EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376: 32-40. doi: 10.1056/NEJMoa1611688
  27. Johnston S.C, Amarenco P, Albers G.W, Denison H, Easton J.D, Evans S.R, et al; for the SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375:35-43. doi: 10.1056/NEJMc1610106
  28. Кашталап В.В., Барбараш О.Л. Актуальные проблемы антитромботической терапии при остром коронарном синдроме (по материалам Европейского конгресса кардиологов 2017 г.). Медицинский совет. 2017;(12):82-8. doi: 10.21518/2079-701X-2017-12-82-88/
  29. Bhatt D.L, Flather M.D, Hacke W, Berger P.B, Black H.R, Boden W.E, et al; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-8. doi: 10.1016/j. jacc.2007.03.025

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies